Vivera Pharmaceuticals, Inc. is an innovative, science-driven pharmaceutical company focused on novel therapies for a variety of indications. The Company is composed of seven divisions, each with a unique mission yet working synergistically to support Vivera’s core mission of putting patients first.  From day one, Vivera Pharmaceuticals’ mission has been to put our patients first. From the opioid crisis to COVID-19 and beyond, Vivera’s team is developing new therapeutics and novel medical device technologies. We strive to fulfill our purpose- and our promise. We are committed to patient-centric research and development

At the onset of 2020, Vivera’s core business centered around three divisions: Pharmaceuticals, Medical Device, and Health and Human Services. Today, we have more than doubled that to include our Advanced Diagnostics, Medical Technologies, Medical Supplies, and Neuroscience divisions, each focused on addressing a specific need.  

Within our Advanced Diagnostics division, we have developed a portfolio of USA-made testing for COVID-19. Medical Technologies brings innovative devices to complement telehealth and sanitation endeavors. Complementing our access to medical supplies throughout the pandemic, Vivera® has partnered to supply needed medical products for the pandemic and beyond through its Medical Supplies division. Our newest division, Vivera Neurosciences, is focused on utilizing the TABMELT™ technology to expand therapies for a range of psychiatric ailments. 

Despite our growth, Vivera has not deviated from its founding focus on non-addictive pain management therapies. In addition to our pharmaceutical and medical device products, Vivera has global exclusivity to license the patented and provisionally patented, TABMELT® sublingual drug-delivery system for pharmaceutical use. Initial case studies and clinical trials utilizing the TABMELT® platform are underway.